Introduction {#s1}
============

The major epidemic of chikungunya virus fever (chikungunya) that affected 266,000 people in La Réunion in 2006 highlighted the vulnerability of immunologically naive populations and raised interest in this disease in the media, governments, and the scientific community [@pntd.0001446-Enserink1]. Over and above the number of cases, with one-third of the population affected, this epidemic revealed new features of chikungunya pathogenesis.

An adaptive mutation in the virus led to *Aedes albopictus* becoming a major vector for chikungunya virus (CHIKV) [@pntd.0001446-Tsetsarkin1], resulting in a risk of disease in previously unaffected areas. In addition, other new or previously underestimated features of the virus have also come to light in recent chikungunya epidemics. Atypical symptoms were observed in the La Réunion epidemic ([Table 1](#pntd-0001446-t001){ref-type="table"}), albeit in a small percentage of patients (\<0.3% [@pntd.0001446-Economopoulou1], [@pntd.0001446-Dominguez1]). However, more importantly, this epidemic highlighted the persistence of chronic features in a significant proportion of patients, as first reported in the early 1980s [@pntd.0001446-Borgherini1]--[@pntd.0001446-Fourie1] but not investigated further. These chronic signs of chikungunya are disabling and merit further attention, because there is currently no recommended treatment for chikungunya based on clinical trials [@pntd.0001446-Delogu1]--[@pntd.0001446-Herrero1]. Treatment instead depends on the response of the patient, ranging from non-steroidal anti-inflammatory drugs, to re-education, to simple rest [@pntd.0001446-Pialoux1], [@pntd.0001446-Murhekar1].

10.1371/journal.pntd.0001446.t001

###### Acute chikungunya symptoms in typical and atypical forms in adults, children, and newborns.

![](pntd.0001446.t001){#pntd-0001446-t001-1}

  Setting                                                                                                                    La Réunion and Indian Ocean Islands [@pntd.0001446-Economopoulou1], [@pntd.0001446-Dominguez1], [@pntd.0001446-Pialoux1], [@pntd.0001446-Sergon1], [@pntd.0001446-Sergon2], [@pntd.0001446-Pialoux2]--[@pntd.0001446-Powers1]   India [@pntd.0001446-Manimunda1], [@pntd.0001446-Chopra1], [@pntd.0001446-Manimunda2], [@pntd.0001446-Rampal1]--[@pntd.0001446-Manimunda3]     Singapore [@pntd.0001446-Win1]       Malaysia [@pntd.0001446-Ayu1], [@pntd.0001446-Chua1]
  ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ -----------------------------------------------------------
  ***Mean age (year)***                                                                                                                                                                                                                  34±20                                                                                                                                                                              35 (median)                                                                               37(median)                                        35.9±18
  ***Sex ratio (male/female)***                                                                                                                                                                                                          0.84                                                                                                                                                                                0.6 -- 0.9                                                                                  3.4                                         0.82 -- 1.03
  ***Typical form symptoms % (common before 2006)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Fever                                                                                                                                                                                                                                   100                                                                                                                                                                                81 -- 100                                                                                    90                                           86 -- 100
  Arthralgia *joint pain*/*swelling*                                                                                                                                                                                                      100                                                                                                                                                                                 86 -- 80                                                                                    88                                           82 -- 100
  Cephalalgia *headache*                                                                                                                                                                                                                  70                                                                                                                                                                                     93                                                                                       43                                           30 -- 50
  Myalgia *muscle pain*                                                                                                                                                                                                                   64                                                                                                                                                                                  48 -- 84                                                                                    61                                           10 -- 48
  Rash                                                                                                                                                                                                                                    39                                                                                                                                                                                  36 -- 50                                                                                    36                                        64 -- 17 -- 50
  Erythema                                                                                                                                                                                                                                33                                                                                                                                                                                    ---                                                                                                           
  Asthenia *fatigue*                                                                                                                                                                                                                      67                                                                                                                                                                                     43                                                                                                           
  ***Atypical Symptoms % (as defined in La Réunion;*** [@pntd.0001446-Economopoulou1], [@pntd.0001446-Dominguez1] ***)***                                                              *n* = 876; atypical form is 36% of severe acute chikungunya but less than 0.3% total cases in La Réunion                                                                                                                                                                                                                                               
  Maculopapular eruption                                                                                                                                                                                                                  33                                                                                                                                                                                     17                                                                                                           
  Meningo-encephalitis                                                                                                                                                                                                                    16                                                                                                                                                                                     25                                                                                                           
  Diarrhea / vomiting                                                                                                                                                                                                                     18                                                                                                                                                                                    12/4                                                                                     3/8                  
  Renal failure                                                                                                                                                                                                                           20                                                                                                                                                                                    ---                                                                                                           
  Respiratory failure                                                                                                                                                                                                                     16                                                                                                                                                                                    ---                                                                                                           
  Myocarditis / pericarditis                                                                                                                                                                                                               6                                                                                                                                                                                     11                                                                                                           
  Hepatitis                                                                                                                                                                                                                                6                                                                                                                                                                                    ---                                                                                                            Yes[a](#nt101){ref-type="table-fn"} [@pntd.0001446-Chua2]
  Sensory changes (muffling of noise, sensitivity to light)                                                                                                                                                                                9                                                                                                                                                                                     33                                                                                                           
  Aphtous-like ulcer                                                                                                                                                                                                                      ---                                                                                                                                                                                    21                                                                                                           
  Hyperpigmentation                                                                                                                                                                                                                       15                                                                                                                                                                                     20                                                                                                           
  Genital ulcers                                                                                                                                                                                                                          ---                                                                                                                                                                                    1                                                                                                            
  Optic neuritis                                                                                                                                                                                                                          \<1                                                                                                                                                                                   \<1                                                                       11[b](#nt102){ref-type="table-fn"}  
  Facial paralysis                                                                                                                                                                                                                        ---                                                                                                                                                                                    2                                                                                                            
  Guillain-Barre syndrome                                                                                                                                                                                                                  1                                                                                                                                                         Yes[a](#nt101){ref-type="table-fn"} [@pntd.0001446-Singh1]                                                                               
  ***Atypical symptoms in young children %***                                                                                                                                                     [@pntd.0001446-Economopoulou1], [@pntd.0001446-Gerardin2], [@pntd.0001446-LeBomin1]                                                                                                                 [@pntd.0001446-Inamadar1], [@pntd.0001446-SajithKumar1]                                                                                 
  Hyperalgia *high grade pain*                                                                                                                                                                                                            27                                                                                                                                                                    Yes[a](#nt101){ref-type="table-fn"}                                                                                           
  Diarrhea/vomiting                                                                                                                                                                                                                       27                                                                                                                                                                    Yes[a](#nt101){ref-type="table-fn"}                                                                                           
  Convulsions                                                                                                                                                                                                                             22                                                                                                                                                                    Yes[a](#nt101){ref-type="table-fn"}                                                                                           
  Bullous dermatosis                                                                                                                                                                                                                      17                                                                                                                                                                    Yes[a](#nt101){ref-type="table-fn"}                                                                                           
  Purpura                                                                                                                                                                                                                                  8                                                                                                                                                                    Yes[a](#nt101){ref-type="table-fn"}                                                                                           
  Encephalitis                                                                                                                                                                                                                             6                                                                                                                                                                    Yes[a](#nt101){ref-type="table-fn"}                                                                                           

Atypical forms were noticed but their prevalence was not evaluated.

Retro-orbital pain.

We aim here to present current knowledge on CHIKV infection and related aspects, such as the inflammatory response which potentially leads to the development of chronic syndromes.

Clinical Symptoms, from Acute to Chronic Chikungunya {#s2}
====================================================

CHIKV spreads rapidly in the body after initial infection ([Figure 1](#pntd-0001446-g001){ref-type="fig"}). The clinical signs of acute infection are not entirely specific and may vary between cohorts ([Table 1](#pntd-0001446-t001){ref-type="table"}). A small but significant number of infected people present asymptomatic infection (5% to 18% [@pntd.0001446-Manimunda1]--[@pntd.0001446-Moro1]), significantly more often below 25 years [@pntd.0001446-Chopra1], [@pntd.0001446-Sissoko2]. However, concomitant fever and arthralgia is a common specific sign [@pntd.0001446-Gerardin1], [@pntd.0001446-Sissoko2]--[@pntd.0001446-Sergon2]. The La Réunion epidemic highlighted various "new" symptoms considered atypical and frequently associated with severe forms, other than in very rare cases of vertical transmission ([Table 1](#pntd-0001446-t001){ref-type="table"}) [@pntd.0001446-Gerardin2]. Most of these symptoms were also observed in India and in travelers returning from areas of endemic disease [@pntd.0001446-Simon1], [@pntd.0001446-Panning1]--[@pntd.0001446-Mizuno1].

![Virus dissemination and target organs.\
Following inoculation with CHIKV through a mosquito bite, the virus directly enters the subcutaneous capillaries, with some viruses infecting susceptible cells in the skin, such as macrophages or fibroblasts and endothelial cells. Local viral replication seems to be minor and limited in time, with the locally produced virus probably being transported to secondary lymphoid organs close to the site of inoculation. The blood carries most viruses, as free virions or in the form of infected monocytes, to the target organs, the liver, muscle, joints, and remote lymphoid organs. In these tissues, infection is associated with a marked infiltration of mononuclear cells, including macrophages, particularly when viral replication occurs. The pathological events associated with tissue infection are mostly subclinical in the liver (hepatocyte apoptosis) and lymphoid organs (adenopathy), whereas mononuclear cell infiltration and viral replication in the muscles and joints are associated with very strong pain, with some of the patients presenting arthritis. \* Guillain-Barré syndrome and encephalitis are very rare events. † True arthritis remains a rare event (from 2% to 10%); see [Table 2](#pntd-0001446-t002){ref-type="table"}.](pntd.0001446.g001){#pntd-0001446-g001}

Acute-phase symptoms usually disappear after 2 weeks. However, arthralgia and/or myalgia may persist for weeks, months, or even years. Some patients go on to develop a genuine, chronic arthritic syndrome. Typically, joint damage fluctuates over time, but always affects the same parts of the body, mostly the extremities (hands, ankles, knuckles; [Table 2](#pntd-0001446-t002){ref-type="table"}) [@pntd.0001446-Borgherini1], [@pntd.0001446-Simon1], [@pntd.0001446-Sissoko1], [@pntd.0001446-Mizuno1], [@pntd.0001446-Manimunda2]. Chronic chikungunya has been described before, but the La Réunion epidemic brought it to public attention. In 1979, Fourie and Morrison described a rheumatoid arthritic syndrome affecting 18% of patients in South Africa [@pntd.0001446-Fourie1]. Their observations were confirmed in 1983 by Brighton et al., who reported that 12% of patients with CHIKV in South Africa continued to display rheumatic manifestations years after the acute phase [@pntd.0001446-Brighton1]. Being over the age of 40 years was identified as a risk factor for chronicity. This rheumatic syndrome may reflect the ability of CHIKV to persist in some compartments by mechanisms that remain poorly understood.

10.1371/journal.pntd.0001446.t002

###### Chronic chikungunya symptoms.

![](pntd.0001446.t002){#pntd-0001446-t002-2}

  Setting (Date Referred)                                                                           La Réunion (2005 to 04/2006) [@pntd.0001446-Borgherini1]   La Réunion (04/2006--2007) [@pntd.0001446-Hoarau1], [@pntd.0001446-Moiton1]   India Karmataka (2008) [@pntd.0001446-Manimunda2]   India Maharashtra (2006) [@pntd.0001446-Chopra1]   Singapore (2008) [@pntd.0001446-Chow1], [@pntd.0001446-Win1]
  ------------------------------------------------------------------------------------------------ ---------------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------- --------------------------------------------------------------
  **Number of chronic cases / number of patients in the cohort** ***(month after acute phase)***         56[a](#nt104){ref-type="table-fn"}/88 *(\>18)*                                      116/133 *(12)*                                                   94/203 *(\>9)*                                      59/315 *(12)*                             14[b](#nt105){ref-type="table-fn"}/97 *(3)*
  **Mean age of chronic cases**                                                                                                60                                                              58 (median)                                                          41                                                  48                                                      38±6
  **Sex ratio (M/F in chronic)**                                                                              0.93[c](#nt106){ref-type="table-fn"}                                                0.33                                                             0.81                               0.33[\*](#nt103){ref-type="table-fn"}                                     1.8
  **Hospitalized (%)**                                                                                                        65.9                                                                 85                                                                0                                                  0                                                       100
  **Joint pain (%)**                                                                                                          100                                                                  100                                                              94                                                 100                                                      100
  **Fatigue (%)**                                                                                                              NR                                                                  NR                                                               27                                                  NR                                                       NR
  **Joint swelling/tenosynovitis (%)**                                                                                         16                                                                  NR                                                              58.5                                                 NR                                                       NR
  **Localization**                                                                                                                                                                                                                                                                                                                                                               NR
  **Symmetrical (%)**                                                                                                          64                                                              More often                                                           83                                                  NR                         
  **Knee (self/exam) (%)**                                                                                                  21 (57)                                                                20                                                              59.5                                                 57                         
  **Ankles/wrist (%)**                                                                                                       29/16                                                                31/21                                                            54/31                                              15/59                        
  **Shoulder (%)**                                                                                                             30                                                                  NR                                                               15                                                 52.5                        
  **Hips (%)**                                                                                                                 5                                                                   NR                                                               11                                                  7                          
  **Continuous pain (%)**                                                                                                      55                                                                  68                                                                                                                   NR                                                      100
  **Rheumatoid like polyarthritis (%)**                                                                                        ND                                                                  10                                               36[d](#nt107){ref-type="table-fn"}                               100 NSA                                                     0
  **Spondylo-arthropathy (%)**                                                                                                 ND                                                                  22                                                               IE                                                 7 IA                                                      0
  **Underlying disease (%)**                                                                                                   71                                                             Not detailed                                                  10/20 tested by MRI                                         NR                                                       0
  **Previous arthritis/arthralgia (%)**                                                                                        51                                                                   7                                                                7                                                  5                                                        0

**\*:** *p*\<0.01 Khi-2 between infected time 0 and chronic at 12 months (calculated by us).

Low ALT/ASAT level related to persistence (*p*\<0.01) like platelet count.

Lower level of creatinine *p* = 0.036.

No difference chronic versus recovered.

American College of Rheumatology criteria for rheumatoid arthritis in [@pntd.0001446-Chopra2]; note that tenosynovitis is prominent (as seen by Hoarau et al. [@pntd.0001446-Hoarau1]).

IA, inflammatory arthritis; IE, inflammatory, erosive; MRI, magnetic resonance imaging; ND, not detected or prevalence not evaluated; NR, not reported; NSA, non-specific arthritis.

Following the 2005--2006 epidemic in La Réunion, 36% of patients reported the persistence of symptoms 15 months after disease onset, and 21% reported at least one recurrence [@pntd.0001446-Sissoko1]. In this group, age over 45 years, the pain intensity score (≥7 on a 0--10 scale) during acute disease, and pre-existing osteoarthritis conditions were associated with persistence. However, classification was based on self-perceived recovery from rheumatic manifestations of chikungunya, and it is therefore very difficult to differentiate between osteoarthritis and chikungunya in these patients ([Table 2](#pntd-0001446-t002){ref-type="table"}). Nevertheless, age and pain intensity score remain robust predicting factors. Similar chronic forms of chikungunya had previously been reported in other patient series in La Réunion by Borgherini et al. [@pntd.0001446-Borgherini1] and in travelers returning from Indian Ocean islands by Simon et al. [@pntd.0001446-Simon1]. These late signs may not be specific to the CHIKV strain of the 2005--2006 outbreak, as they were also reported for a closely related viral strain in India, with various frequencies in the 10 months following the acute phase: 16% in Maharashtara and 49% in Karnataka [@pntd.0001446-Chopra1], [@pntd.0001446-Manimunda2] ([Table 2](#pntd-0001446-t002){ref-type="table"}). In Karnataka, Manimunda et al. examined 20 of 94 patients with persistent joint pain by X-ray and MRI: 15% of patients presented chronic inflammatory erosive arthritis after CHIKV infection [@pntd.0001446-Manimunda2]. By contrast, Chopra et al. mostly reported chronic pain, with rare cases of inflammatory arthritis, in a population cohort study; these findings conflict with their previous report on patients hospitalized at a rheumatology referral center [@pntd.0001446-Chopra1], [@pntd.0001446-Chopra2].

Persistent symptoms, including arthralgia, myalgia, and arthritis (consistently found on radiological/MRI examination in various sets of patients, see [Table 2](#pntd-0001446-t002){ref-type="table"} and [@pntd.0001446-Simon1], [@pntd.0001446-Mizuno1]--[@pntd.0001446-Parola1]) suggest the persistence of virus in target organs or the establishment of a self-sustained, deleterious mechanism leading to tissue damage, probably inflammatory in nature. Very little is currently known about the mechanism underlying chikungunya persistence. Studies in animal models and clinical investigations are needed to address this point.

Animal Models {#s3}
=============

The mouse was the first organism used for *in vivo* studies of CHIKV infection [@pntd.0001446-Couderc1], but muscle and joint disease was achieved only recently in this species [@pntd.0001446-Gardner1]--[@pntd.0001446-Rulli1]. Subcutaneous CHIKV inoculation close to distal leg joints in adult C57Bl6 mice leads to a muscle and joint disease, including loss of balance, hind limb dragging, and skin lesions [@pntd.0001446-Gardner1], [@pntd.0001446-Morrison1], [@pntd.0001446-Ziegler1]. This strongly suggests that the initial dissemination of CHIKV ([Figure 1](#pntd-0001446-g001){ref-type="fig"}) is critical to the setting of chikungunya. In this model, and using both Asian and La Réunion strains of CHIKV, Gardner and Morrison demonstrated arthritis, tenosynovitis, and myositis, together with local virus persistence in tissues after the phase of active replication in the blood. Infiltration with monocytes and macrophages is also observed in connective tissues, and subcutaneous peritendinous tissues and muscle, on histological analysis and immunohistochemistry with the F4/80 monoclonal antibody [@pntd.0001446-Gardner1], [@pntd.0001446-Rulli1], [@pntd.0001446-Ziegler1]. In 2006, we developed a model of macaque infection and virus spread ([Figure 1](#pntd-0001446-g001){ref-type="fig"}). This model was required for the rapid implementation of preclinical trials following the La Réunion epidemic and the risk of extension to the Indian Ocean zone. We infected cynomolgus macaques (*Macaca fascicularis*) with CHIKV strain LR-2006-OPY1 from La Réunion [@pntd.0001446-Parola1]. RT-PCR on plasma revealed viral replication kinetics similar to those in humans, together with profound leukopenia consistent with lymphocyte and monocyte recruitment to tissues. Several soluble factors, such as IFNα, IL-6, MCP1/CCL-2, and TNFα, were found to be induced, to various levels, in a multiplex immunoassay [@pntd.0001446-Labadie1]. In this model, acute infection is controlled by the immune response, which renders viral replication undetectable, from 10 days after infection [@pntd.0001446-Labadie1]. However, CHIKV persists in target tissues after its clearance from the blood, as demonstrated by viral RNA detection in an *in situ* hybridization assay using a CHIKV subgenomic mRNA specific probe. Joints, secondary lymphoid organs and, to a lesser extent, muscles, are affected. CHIKV replicates in several cell types during the acute phase [@pntd.0001446-Labadie1], but is thereafter detectable only in macrophages, by immunohistochemical analysis with a monoclonal antibody against the viral E2 glycoprotein. We detected infected monocytes-macrophages in the blood 6 hours after infection (flow cytometry) [@pntd.0001446-Roques1] and in most tissues on the following day (*in situ* hybridization, immunohistochemistry, RT-PCR, and virus isolation). Significant macrophage infiltration was also detected by histological analysis [@pntd.0001446-Labadie1], throughout the study and long after viral clearance from blood. This monocyte-macrophage tropism is consistent with recent findings from Lisa Ng\'s team that human monocytes are susceptible to infection *in vitro*, as shown by flow cytometry with a monoclonal antibody against the E1 glycoprotein of CHIKV. Infected monocytes generate new viruses, which can be detected with HEK293 cells and titration assays, albeit at low levels [@pntd.0001446-Her1]. Similarly, CHIKV can infect primary macrophages *in vitro* [@pntd.0001446-Rinaldo1], [@pntd.0001446-Sourisseau1], resulting in the production of highly variable amounts of virus, from 10^3^ to 10^6^ pfu per ml [@pntd.0001446-Gardner1], [@pntd.0001446-Labadie1], [@pntd.0001446-Sourisseau1], [@pntd.0001446-Solignat1]. These results are consistent with human studies reporting that macrophages are susceptible to CHIKV infection both *in vivo* and *in vitro* [@pntd.0001446-Hoarau1]--[@pntd.0001446-KrejbichTrotot2]. The alleviation of chikungunya-associated arthritis and myositis by treatment with the MCP-1/CCL-2 inhibitor Bindarit in mice [@pntd.0001446-Rulli1] also strongly suggests that monocytes-macrophages, the main targets in MCP-1/CCL-2 tissue tropism, are central to muscle and joint disease.

There is currently no animal model reproducing the chronic rheumatoid syndrome of chikungunya. Indeed, the disease has too short a course in mice [@pntd.0001446-Gardner1], [@pntd.0001446-Morrison1], and no joint damage was evident in macaques [@pntd.0001446-Labadie1], in which only virus persistence in joints, long after the acute phase, could be demonstrated. Nevertheless, both models suggest that inflammation, macrophage tissue tropism, and local viral persistence are involved in the establishment of chronic disease.

Viral Persistence and Clinical Expression {#s4}
=========================================

Recent data have clearly implicated inflammatory mediators not only in the acute and resolution phases of chikungunya, but also in the establishment of chronic disease. [Figure 2](#pntd-0001446-g002){ref-type="fig"} shows how CHIKV infection may lead to chronic joint damage.

![Mechanisms of CHIKV persistence and tissue inflammation in patients with chronic disease.\
(1) Months after the acute infection, monocytes, T cells, and natural killer (NK) cells are still attracted to the inflamed joint, where they become activated. (2) The infection of macrophages in joints is associated with local inflammation and the production of cytokines, chemokines, and pro-inflammatory effectors, such as MCP-1/CCL-2, IL-8, IL-6, IFN-α, and MMP2. (3) The phagocytosis of apoptotic bodies from infected cells probably contributes to viral persistence. Nevertheless, the beneficial or deleterious effect of local inflammation on viral persistence remains unclear. (4) When it occurs, arthritis is accompanied by high rates of fibroblast apoptosis and cartilage destruction. Chronic inflammation probably plays a major role in this damage and associated pain. (5) The potential relationship between local inflammation of the joint and a state of systemic activation, as demonstrated by the presence of inflammation markers in plasma and blood cells, remains unclear.](pntd.0001446.g002){#pntd-0001446-g002}

The Acute Phase {#s4a}
---------------

The first phase of CHIKV infection is typical of acute viral infection, with a very early type 1 interferon (IFN) response [@pntd.0001446-Hoarau1], [@pntd.0001446-Chow1]--[@pntd.0001446-Kelvin1]. IFN-α is detected on the first day of infection and its concentration is correlated with plasma viral load, which is significantly higher in elderly patients [@pntd.0001446-Borgherini2]. However, plasma concentrations of Th1 and Th2 cytokines remain low [@pntd.0001446-Hoarau1], [@pntd.0001446-Chow1]--[@pntd.0001446-Kelvin1], [@pntd.0001446-Chaaitanya1], despite the observation by Hoarau et al. that IFN-γ and IL-12 levels were high in patients from La Réunion [@pntd.0001446-Hoarau1]. Wauquier et al. also reported IFN-γ overproduction, together with IFN-α2, during the acute phase [@pntd.0001446-Wauquier1], in Gabon. Chow et al. showed, in Singapore, that IFN-α was produced for 10 days before viral clearance from plasma, but they detected no IFN-γ in serum [@pntd.0001446-Chow1]. The acute IFN response may be short-lived, as it has not been detected directly in studies otherwise reporting an early increase in levels of the IFN-inducible chemokines MIG/CXCL-9 and IP-10/CXCL-10) [@pntd.0001446-Kelvin1], [@pntd.0001446-Chaaitanya1].

Viral load is related to the concentrations of IFN-α, IL-1-RA, IL-6, MCP-1/CCL-2, IL-12 and IP-10/CXCL-10 [@pntd.0001446-Chow1], IL-18, and IL-18BP [@pntd.0001446-Chirathaworn1]. The inflammatory response to CHIKV infection therefore clearly contributes to virus elimination. Unfortunately, none of the population studies [@pntd.0001446-Chopra1], [@pntd.0001446-Manimunda2], [@pntd.0001446-Hoarau1], [@pntd.0001446-Chow1]--[@pntd.0001446-Kelvin1], [@pntd.0001446-Chaaitanya1] carried out assessed joint or muscle pain, so it is not currently possible to determine the relationship between viral load or inflammatory mediators and symptoms. Wauquier et al. reported markedly higher levels of proinflammatory mediators than other teams [@pntd.0001446-Hoarau1], [@pntd.0001446-Chow1]--[@pntd.0001446-Kelvin1], [@pntd.0001446-Chaaitanya1]. This difference may reflect regional characteristics of the cohorts studied (Gabon versus Italy, La Réunion, India, and Singapore), with different genetic backgrounds and heterogeneous sanitary conditions, but it may also reflect sampling schedule. For example, IL-6 concentration depends largely on sampling time, as observed in our macaque model [@pntd.0001446-Labadie1]. Similarly, IL-12 concentration was high in the Gabon, La Réunion, and Singapore series [@pntd.0001446-Hoarau1], [@pntd.0001446-Chow1], [@pntd.0001446-Wauquier1], but was lower than that in uninfected controls in Italy, although these results may not be directly comparable due to the use of different technologies [@pntd.0001446-Kelvin1]. During the experimental infection of macaques with CHIKV, we observed an early induction of IFN-α, MCP-1/CCL-2, and IL-6, followed by the detection of MIP-1α/CCL-3 and MIP-1β/CCL-4, IFN-γ, and TNF-α. These last two effectors remain at higher concentrations than in controls until the end of the recovery phase (15--20 days post infection) [@pntd.0001446-Labadie1]. In the mouse model developed by Surhbier et al., events follow a similar chronology, but with differences in plasma cytokine concentrations, including higher levels of TNF-α [@pntd.0001446-Gardner1].

The Chronic Phase and Its Predictive Factors {#s4b}
--------------------------------------------

The inflammatory response to CHIKV infection leads to viral elimination from the blood and clinical recovery. However, it is now clear that disease may persist in a subgroup of patients presenting variable levels of myalgia and arthralgia, culminating in some cases in a debilitating arthritic syndrome. Five studies have tried to identify the factors associated with chronic chikungunya disease in groups of patients in Singapore [@pntd.0001446-Chow1], La Réunion [@pntd.0001446-Hoarau1], Dakshina Kannada (India) [@pntd.0001446-Manimunda2], [@pntd.0001446-Chaaitanya1], and Emilia Romagna (Italy) [@pntd.0001446-Kelvin1] ([Table 3](#pntd-0001446-t003){ref-type="table"}), with times measured from inclusion (i.e., first consultation).

10.1371/journal.pntd.0001446.t003

###### Biological parameters associated with disease chronicity in chikungunya patients.

![](pntd.0001446.t003){#pntd-0001446-t003-3}

  Parameter                                                                                           Recovered Patients                                                          Chronic Patients                                              α Risk                                         Series
  ------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------- ----------------------------------------------
  **Age**                                                                                                 50.3±13.7                                                                   70.7±15.5                                                   2%                             La Réunion [@pntd.0001446-Hoarau1]
                                                                                                          40.2±12.3                                                                   31.5±5.2                                                    NS                              Singapore [@pntd.0001446-Chow1]
                                                                                                             34.5                                                                       41.5                                                      NS                        Dakshina Kannada [@pntd.0001446-Chaaitanya1]
                                                                                    Cure rate 10 months after inclusion declining with age                                              \<1‰                                  Dakshina Kannada [@pntd.0001446-Manimunda2]  
  **Acute phase**                                                                                                                                                                                                                                                          
  Viral load at inclusion                                                                         2.3×10^6^±3.7×10^6^ cp/ml                                                   3.9×10^9^±6.9×10^9^ cp/ml                                           5‰                             La Réunion [@pntd.0001446-Hoarau1]
                                                                                                  6.9×10^7^±1.5×10^8^ pfu/ml                                                 1.12×10^4^±5.2×10^3^ pfu/ml                                          NS                              Singapore [@pntd.0001446-Chow1]
  Plasma CRP concentration at inclusion                                                               11.33±10.05 mg/ml                                                            60.2±59.7 mg/ml                                                7%                             La Réunion [@pntd.0001446-Hoarau1]
  Circulating cytokine concentrations at inclusion                                                  Th1 and Th2, moderate                                                      Trend toward a Th1 bias                                            NS                             La Réunion [@pntd.0001446-Hoarau1]
  **Recovery phase**                                                                                                                                                                                                                                                       
  Circulating GM-CSF, 2--3 months post inclusion                                                            Normal                                                              Higher than controls                                             \<5%                             Singapore [@pntd.0001446-Chow1]
  Circulating eotaxin and HGF, 2--3 months post inclusion                                            Higher than controls                                                              Normal                                                    \<5%                             Singapore [@pntd.0001446-Chow1]
  Circulating IL-6, 2--3 months post inclusion                                                       Lower than controls                                                               Normal                                                    \<5%                             Singapore [@pntd.0001446-Chow1]
  **Chronic phase**                                                                                                                                                                                                                                                        
  Circulating IL-12 p40 post acute phase                                                                Not detectable                                                          Persistent (±1 ng/ml)                            0.5‰[a](#nt109){ref-type="table-fn"}            La Réunion [@pntd.0001446-Hoarau1]
  Circulating MIG/CXCL-9 and IP-10/CXCL-10, 6 months post inclusion        Higher in patients with chronic disease than in fully recovered patients                                     \<5%                                    Emilia Romagna [@pntd.0001446-Kelvin1]     
  CHIKV-specific IgG titer, 6 months post inclusion                        Higher in patients with chronic disease than in fully recovered patients                                     \<5%                                    Emilia Romagna [@pntd.0001446-Kelvin1]     
  Circulating cytokines, 10--12 months post inclusion                                                Th2 (increased IL-5)                                 Th1: IL-1β, IL-1RA, IL-6, MCP-1/CCL-2, MIP-1α/CCL-3, MIP-1β/CCL-4                      \<5%                       Dakshina Kannada [@pntd.0001446-Chaaitanya1]
                                                                       No difference between patients with chronic disease and fully recovered patients                                  NS                                     Emilia Romagna [@pntd.0001446-Kelvin1]     
  IFN-α mRNA in PBMC, 12 months post inclusion                                                          Not detectable                                                               High levels                                  2%[a](#nt109){ref-type="table-fn"}             La Réunion [@pntd.0001446-Hoarau1]
  **Joint tissue**                                                                                                                                                                                                                                                         
  CHIKV detection in the joint at late time points (\>12 months)                                              No                                                                 Yes, in macrophages                                              NA                             La Réunion [@pntd.0001446-Hoarau1]
  Joint inflammation at late time points (\>12 months)                                                        No                                                        MCP-1/CCL-2, IL-8, IL-6, MMP2, IFN-α                                      NA                             La Réunion [@pntd.0001446-Hoarau1]

Mann and Whitney test performed by us.

Inclusion: first presentation of the patient during acute disease.

Numbers (and sex ratios) of patients with chronic disease were 5 (4) in Singapore, 32 (0.15) in La Réunion, 94 (0.82) in Dakshina Kannada, and 35 (sex ratio not available) in Emilia Romagna.

cp, viral RNA copies; CRP, C reactive protein; NA, not applicable; NS, not significant; pfu, plaque-forming units.

The proportion of patients with chronic signs attributable to CHIKV differed between series. In Singapore, 13% of the infected patients still had chronic arthralgia 3 months after infection [@pntd.0001446-Chow1]. In Emilia Romagna,70% of patients had symptoms persisting at 6 months and 32% had symptoms persisting at 12 months after inclusion [@pntd.0001446-Kelvin1]. Similarly, 49% of patients in the 2008 outbreak in Dakshina Kannada still had symptoms attributable to chikungunya 10 months after inclusion [@pntd.0001446-Manimunda2], and almost half the studied patients from La Réunion had persistent symptoms, possibly including arthritis, 1 year after inclusion [@pntd.0001446-Hoarau1].

Patients with chronic symptoms differ considerably in acute infection characteristics. Hoarau et al. reported high baseline viral loads in patients with chronic disease (10 versus 2.1×10^9^ copies/ml, *p* = 0.005), whereas the opposite trend was reported in Singapore. Viral load was not considered in the Emilia Romagna and Dakshina Kannada series.

Patient age appeared to be crucial in the La Réunion and Dakshina Kannada groups, but not in Singapore (see [Table 3](#pntd-0001446-t003){ref-type="table"}). Patients with chronic chikungunya were older than those who recovered fully in La Réunion [@pntd.0001446-Hoarau1], whereas cure rate at 10 months decreased with age in Dakshina Kannada [@pntd.0001446-Manimunda2].

Hoarau et al. also suggested a link between chronic disease and a stronger inflammatory Th1 response to acute infection ([Table 3](#pntd-0001446-t003){ref-type="table"}). Patients with chronic disease displayed stronger systemic inflammation during the acute phase (higher CRP levels, *p* = 0.07), potentially associated with higher levels of TNF-α, IL-8, IL-6, and IL-12, although these differences were not significant [@pntd.0001446-Hoarau1]. Conversely, the Th2 cytokines IL-4 and IL-13 tended to be produced in smaller amounts during the acute phase in patients progressing to chronic disease.

The recovery period lies between the acute and chronic phases. During this period, active regulatory mechanisms responsible for the resolution of inflammation take place. These mechanisms mostly involve macrophages and their unique ability to arouse and regulate inflammation ([Figure 3](#pntd-0001446-g003){ref-type="fig"}). Chow et al. distinguished early (4 days after inclusion) and late (10 days after inclusion) convalescent phases, whereas Hoarau et al. measured cytokine levels 15 days after inclusion, corresponding roughly to the late convalescent phase. Chow et al. reported the upregulation of both pro-inflammatory and regulatory mediators (IL-2R, IL-4, MIG/CXCL-9, MIP-1α/CCL-3, hepatocyte growth factor \[HGF\], basic fibroblast growth factor \[bFGF\], granulocyte colony-stimulating factor \[G-CSF\], and eotaxin/CCL-11) during the early phase of convalescence. During the late convalescent phase, epidermal growth factor \[EGF\] and RANTES/CCL-5 concentrations peaked in patients from Singapore and IFN-γ and IL-12 were overproduced in patients from La Réunion.

![The macrophage is central to chronic signs of chikungunya disease.\
Macrophage infiltration, under the control of MCP-1/CCL-2, is a critical feature of damaged tissues. The inflammatory effectors IL-6, IL-8, MCP-1/CCL-2, MMP2, and INF-α are specifically expressed in the tissues of patients with chronic chikungunya, who have high IFN-α and IL-12 mRNA levels in their circulating leukocytes. This classical inflammatory process may be regulated by HGF and eotaxin, which have different expression profiles during the recovery phase in patients with chikungunya, depending on whether or not these patients go on to develop chronic disease. HGF also promotes muscle regeneration. Once they have infiltrated the joint or muscle, the macrophages are activated and regulate the local Th1/Th2 balance as a function of their own activation status (classical/M1 or alternative/M2). GM-CSF and HGF, which have M1 and M2 effector activities, respectively, may modulate this balance as they are differentially expressed in acute and chronic chikungunya. CHIKV persists in infected macrophages only in patients with a chronic rheumatic syndrome. The reciprocal influences connecting viral persistence and local inflammation are not known. Solid arrows: activation. Solid stopped lines: regulation. Dotted arrows: expression.](pntd.0001446.g003){#pntd-0001446-g003}

The recovery phase appears to play a critical role in the establishment of chronic disease, at least in patients from Singapore. Chow et al. found higher GM-CSF (granulocyte-macrophage colony-stimulating factor) concentrations in patients subsequently displaying chronic symptoms than in those who fully recovered and the control group [@pntd.0001446-Chow1]. This is consistent with the role of GM-CSF as a proinflammatory mediator in rheumatoid arthritis [@pntd.0001446-Boyd1], [@pntd.0001446-Cornish1] and in the activation of monocytes-macrophages [@pntd.0001446-Porcheray1]. Conversely, during convalescence, cured patients continued to have significantly higher levels of HGF and eotaxin/CCL-11 than control subjects and patients with chronic pain syndrome. Eotaxin is a Th2 chemokine and natural antagonist of CCR-2, the receptor for MCP-1/CCL-2 [@pntd.0001446-Ogilvie1], whereas HGF inhibits the production of MCP-1/CCL-2 in response to TNF-α *in vitro* [@pntd.0001446-Shintani1]. The concomitant overproduction of eotaxin and HGH therefore probably reflects the inhibition of MCP-1/CCL-2 signaling via CCR-2. MCP-1/CCL-2 is a major chemoattractant for monocytes-macrophages. It is strongly expressed during acute infection in humans and in animal models [@pntd.0001446-Gardner1], [@pntd.0001446-Labadie1], [@pntd.0001446-Kelvin1], [@pntd.0001446-Chaaitanya1], [@pntd.0001446-Lidbury1], [@pntd.0001446-Rulli2]. It is the target of the pharmacological inhibitor Bindarit, a molecule that alleviates chikungunya arthritis and myositis in the mouse model [@pntd.0001446-Rulli1]. During recovery, plasma MCP-1/CCL-2 concentration decreases, remaining slightly (and non-significantly) above normal levels 2--3 months later. The high levels of eotaxin and HGF production in patients attaining full remission [@pntd.0001446-Chow1], and the beneficial effects of CCR-2 inhibition in the mouse model [@pntd.0001446-Rulli1], strongly suggest that recovery requires the inhibition of signaling downstream from CCR-2, preventing monocyte-macrophage recruitment to tissues ([Figures 2](#pntd-0001446-g002){ref-type="fig"} and [3](#pntd-0001446-g003){ref-type="fig"}).

HGF also has beneficial effects on muscle regeneration [@pntd.0001446-Sugiura1]. It regulates the IL-6/IL-10 balance in favor of IL-10 in various models [@pntd.0001446-Shintani1], [@pntd.0001446-Kamimoto1], [@pntd.0001446-Coudriet1], probably by inhibiting NFκB [@pntd.0001446-Bendinelli1]. HGF overproduction may therefore account for the low IL-6 concentrations in patients fully recovering in Singapore and the small number of severe cases in this group. A Th2-type response in patients that recovered (10 months after inclusion) was also described by Chaaithanya et al. [@pntd.0001446-Chaaitanya1]. Conversely, a deficit of HGF may account for the persistence of high IL-6 levels in the chronic phase, both systemically [@pntd.0001446-Chopra1], [@pntd.0001446-Chaaitanya1] and locally [@pntd.0001446-Hoarau1]. IL-6 is involved in joint pain [@pntd.0001446-Schaible1] and rheumatoid arthritis [@pntd.0001446-Alonzi1], and it increases the production of cartilage-destroying enzymes [@pntd.0001446-Klareskog1].

In addition to IL-6, chronic chikungunya (\>6 months) is also associated with other systemic markers of inflammation, such as IFN-α [@pntd.0001446-Hoarau1], the IFN-inducible chemokines MIG/CXCL-9 and IP-10/CXCL-10 [@pntd.0001446-Kelvin1], and the cytokines IL-1β, IL-1RA, IL-6, CCL-2/MCP-1, CCL-3/MIP-1α, CCL-4/MIP-1β [@pntd.0001446-Chaaitanya1], IL-12 [@pntd.0001446-Hoarau1], and IL-17 [@pntd.0001446-Chow1]. Th1-type activation has also been observed in altered joint tissues, in which it is associated with viral persistence in macrophages [@pntd.0001446-Hoarau1] ([Figure 2](#pntd-0001446-g002){ref-type="fig"}).

These data highlight the role of macrophages in chronic arthralgia and arthritis as a virus reservoir and as the main local cell type involved in regulating inflammation and Th1/Th2 balance. The central role of macrophages in chronic chikungunya disease and various pathogenic pathways involved are illustrated in [Figure 3](#pntd-0001446-g003){ref-type="fig"}.

Conclusion {#s5}
==========

Regulatory mechanisms seem to be required to prevent the establishment of chronic disease weeks or even months after viral clearance from the blood. The absence of such mechanisms leads to chronic arthralgia, or the arthritis observed in the group from La Réunion. Hoarau et al. detected CHIKV and various markers of inflammation (IFN-α, IL-6, MCP-1/CCL-2, IL-8, and MMP2) in the synovium of a patient suffering from chronic pain, but not in synovium of two patients who recovered fully [@pntd.0001446-Hoarau1]. The persistence of a local reservoir of CHIKV in joints may therefore be characteristic of chronic disease (see [Figures 2](#pntd-0001446-g002){ref-type="fig"} and [3](#pntd-0001446-g003){ref-type="fig"}). This persistence is consistent with findings in the macaque model, in which CHIKV is detected after up to 90 days in tissues, including joint tissues [@pntd.0001446-Labadie1].

The persistence of CHIKV in joints may therefore lead to chronic local inflammation, causing pain. Local inflammation would in turn establish local conditions favoring CHIKV persistence. Indeed, we know from HIV/AIDS studies [@pntd.0001446-Biswas1], [@pntd.0001446-Dhawan1] that inflammation contributes to the destruction and elimination of viruses, but may also maintain the levels of activation required for sustained replication and viral persistence in tissues, particularly in macrophages, a cell target common to HIV and CHIKV. Thus, CHIKV persistence may therefore also result from an imperfectly resolved inflammatory phase, through the ingestion of apoptotic cells by macrophages and skewed activation, for example [@pntd.0001446-KrejbichTrotot1], [@pntd.0001446-Fadok1].

Hoarau et al. reported high plasma concentrations of IL-12 and IFN-α mRNA in blood mononuclear cells after the convalescence phase, in patients with chronic disease, between 6 months and 1 year after infection. In the patients from Singapore, the concentrations of these two cytokines, measured by alternative techniques, peaked in the acute phase and returned to normal levels at 2--3 months, even in patients who still had clinical symptoms. Consistent with the findings of Hoarau et al., Kelvin et al. and Chaaithanya et al. reported high levels of Th1-type cytokines in the blood of patients with chronic disease (see [Table 3](#pntd-0001446-t003){ref-type="table"}). It would thus be extremely interesting to obtain data for larger groups of patients, to determine precisely the cytokine profiles associated with chronic disease. These profiles would constitute a powerful prognostic tool, facilitating preventive treatment and relevant targeted immunomodulatory treatment. Thus, despite certain discrepancies, the available studies analyzed here suggest that chronic disease requires a defect in the regulation of inflammation during the acute and convalescence phases. This lack of regulation results in a deleterious inflammatory process that persists for at least 1 year after the first clinical signs.
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-   Chronic signs of chikungunya disease.

-   What animal models tell about chikungunya virus persistence.

-   Relationship between inflammatory response to infection and chronic rheumatic syndrome.
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